Strides Pharma Science Ltd
Q1 FY27, unaudited
- Revenue
- ₹1,265.41 Cr
- Profit after tax
- ₹165.49 Cr
As filed with the exchange, consolidated basis.
Statement of profit and loss
Figures in ₹ crore, reproduced from the results data files the company filed with NSE under Regulation 33 of the SEBI (LODR) Regulations. Nothing is restated, adjusted or estimated.
| ₹ crore | Q1 FY27 | vs a year ago | FY26 |
|---|---|---|---|
| Revenue from operations | 1,265.41 | +13.01% | 4,858.68 |
| Other income | 4.89 | −43.03% | 150.71 |
| Total income | 1,270.30 | +12.58% | 5,009.40 |
| Employee benefit expense | 242.99 | +7.75% | 928.96 |
| Finance costs | 40.56 | −14.54% | 178.55 |
| Depreciation & amortisation | 56.40 | +15.37% | 202.40 |
| Total expenses | 1,132.59 | +13.49% | 4,314.34 |
| Profit before tax | 200.90 | +64.75% | 668.22 |
| Tax expense | 34.12 | +107.43% | 94.17 |
| Profit after tax | 165.49 | +56.73% | 574.52 |
| Total comprehensive income | 194.41 | +34.74% | 618.54 |
| Earnings per share, basic | ₹17.02 | ₹60.34 |
|---|---|---|
| Earnings per share, diluted | ₹17.02 | ₹60.34 |
Earnings call
Q4 FY26Strides Pharma Science reported FY26 revenue of INR48,587 million, up 6.4% year-on-year, with EBITDA of INR925 crores growing 15% and EBITDA margin expanding to 19%. Management attributed the revenue shortfall against expectations to a weaker US flu season and donor funding challenges in access markets, while highlighting 21% growth in Ex-US markets and a shift in revenue mix toward Ex-US business. The company also announced the appointment of Ramaraju, current COO, as Executive Director, and the Board recommended a dividend of INR5 per share.
Generated by AI from the filed transcript; every statement on the full page carries its verbatim quote. Read the cited summary
Filings
12 shown · 48 published by the exchange
19 Aug 2026
18 Aug 2026
14 Aug 2026
03 Aug 2026
01 Aug 2026
Filing31 Jul 2026
31 Jul 2026
Presentation31 Jul 2026
31 Jul 2026
24 Jul 2026
24 Jul 2026
21 Jul 2026
BSE corporate announcements, classified by Parakho. The exchange’s own category is kept alongside our classification so a reclassification never rewrites history.
Page generated from filings held to 19 Aug 2026.